Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Respiratory Syncytial Virus (rsv) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

62 recruiting trials for Respiratory Syncytial Virus (rsv). Eligibility criteria explained in plain English.

TrialFinderData lists 62 Respiratory Syncytial Virus (rsv) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 36% (12 studies); the largest phase groups are Phase 3: 12, Phase 2: 10, Phase 1 / Phase 2: 4, Phase 4: 3.

Research is led by Assistance Publique - Hôpitaux de Paris (4), Sanofi (3), Pfizer (2), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (other, 13 trials), followed by Nirsevimab, Peginterferon α-2b injection.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
62
Total Trials
62
Recruiting Now
12
Phase 3 Trials
10
Sponsors

Track Respiratory Syncytial Virus (rsv) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 4NCT07097012

Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy

The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in...

Sponsor: Canadian Immunization Research NetworkEnrolling: 604 locations
RECRUITINGPhase 1 / Phase 2NCT06684379

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With...

The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture...

Sponsor: PEACHES BIOTECHEnrolling: 503 locations
RECRUITINGPhase 3NCT07402512

A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children

This is a randomized, double-blind, placebo-controlled, parallel-group trial conducted in infants and young children aged 1 to 36 months with RSV infection. A total of 498...

Sponsor: Simcere Pharmaceutical Co., LtdEnrolling: 4984 locations
RECRUITINGPhase 3NCT06955728

A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower...

Respiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death -...

Sponsor: University of Witwatersrand, South AfricaEnrolling: 1300011 locations
RECRUITINGNCT07171164

A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults

In collaboration with community-based organizations, this study will focus on increasing RSV vaccine use among Latinos. The study will determine how effective community health...

Sponsor: University of California, San FranciscoEnrolling: 7501 location
RECRUITINGNCT06161285

Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants

Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV). Furthermore, given the same medical history, it...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1203 locations
RECRUITINGNCT07653347

Infant RSV Immunity Study

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection....

Sponsor: University of British ColumbiaEnrolling: 3001 location
RECRUITINGPhase 1NCT06843317

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity...

Sponsor: Clover Biopharmaceuticals USA, LLCEnrolling: 1605 locations
RECRUITINGPhase 3NCT06866405

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a...

This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose...

Sponsor: PfizerEnrolling: 55020 locations
RECRUITINGNCT07239583

Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )

This observational, prospective, multicenter study aims to estimate the proportion of RSV infection in adults aged 60 years and older hospitalized due to acute respiratory...

Sponsor: Tam Anh Research InstituteEnrolling: 10001 location
RECRUITINGNCT07615192

RSV Immunisation Status in Queensland (Australia)

The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention...

Sponsor: SanofiEnrolling: 12001 location
RECRUITINGPhase 2NCT06999603

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

The goal of this Phase 2 study is to assess about the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation...

Sponsor: Synairgen Research Ltd.Enrolling: 55020 locations
RECRUITINGNCT07200206

A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

This study is conducted as part of the local risk management plan to collect and understand the following information about the surveillance drug under the real-world clinical...

Sponsor: SanofiEnrolling: 30001 location
RECRUITINGPhase 1NCT07516418

Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants...

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5...

Sponsor: SanofiEnrolling: 5706 locations
RECRUITINGPhase 1 / Phase 2NCT06754605

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

This is a randomised, double-blind, placebo-controlled Phase 1/2 clinical trial to evaluate the safety, tolerability and immunogenicity of recombinant respiratory syncytial virus...

Sponsor: Sinocelltech Ltd.Enrolling: 4802 locations
RECRUITINGPhase 2NCT07050732

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune...

Sponsor: Johns Hopkins UniversityEnrolling: 1701 location
RECRUITINGPhase 3NCT06363370

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract...

To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.

Sponsor: Kexing Biopharm Co., Ltd.Enrolling: 3221 location
RECRUITINGNCT06881953

Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France

Bronchiolitis is a viral lower respiratory tract infection, caused in 50 to 80% of cases by the respiratory syncytial virus (RSV). Although generally mild, RSV bronchiolitis...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 4001 location
RECRUITINGPhase 2NCT06488300

Assessing Antiviral Treatments in Early Symptomatic RSV

This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated Respiratory...

Sponsor: University of OxfordEnrolling: 10002 locations
RECRUITINGPhase 3NCT07220109

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to...

The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory...

Sponsor: GlaxoSmithKlineEnrolling: 75015 locations
RECRUITINGNCT06160128

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods...

Sponsor: VA Office of Research and DevelopmentEnrolling: 4000001 location
RECRUITINGPhase 4NCT05045612

Antibiotic Therapy in Viral Airway Infections

Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required to reduce the use of broad-spectrum antibiotics with 30% by...

Sponsor: University Hospital, AkershusEnrolling: 38012 locations
RECRUITINGNCT04743609

RSV Burden in Outpatient and Hospital Settings

Strengthening outpatient low respiratory tract infection surveillance to document the burden of Respiratory Syncytial Virus (RSV)

Sponsor: Association Clinique Thérapeutique Infantile du val de MarneEnrolling: 19001 location
RECRUITINGNCT07030075

SURVEILLANCE, ASSESSMENT AND DETECTION OF INFLUENZA ASSOCIATED RESPIRATORY INFECTIONS IN HIV POSITIVE AND NEGATIVE...

Background and rationale:The World Health Organisation (WHO), estimates influenza global deaths at 290,000 to 650,000 annually. Although influenza is mostly associated with upper...

Sponsor: Centre for Infectious Disease Research in ZambiaEnrolling: 5942 locations
RECRUITINGPhase 3NCT05026749

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be...

Sponsor: University of Alabama at BirminghamEnrolling: 37015 locations
RECRUITINGNCT06735612

Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study

The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients...

Sponsor: Fundacio Privada Mon Clinic BarcelonaEnrolling: 8921 location
RECRUITINGNCT07358910

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure...

Sponsor: Institut Pasteur du CambodgeEnrolling: 100001 location
RECRUITINGPhase 1 / Phase 2NCT05655182

A Study of BLB-201 RSV Vaccine in Infants and Children

This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of...

Sponsor: Blue Lake Biotechnology Inc.Enrolling: 13715 locations
RECRUITINGPhase 3NCT07272434

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of...

Sponsor: MAXVAX Biotechnology Limited Liability CompanyEnrolling: 250008 locations
RECRUITINGPhase 3NCT07232706

Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination

RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months. Most people with RSV infection get...

Sponsor: Centre Hospitalier Annecy GenevoisEnrolling: 10001 location
RECRUITINGNCT06856967

Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.

This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8...

Sponsor: Meyer Children's Hospital IRCCSEnrolling: 1388 locations
RECRUITINGPhase 1 / Phase 2NCT07582796

Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.

The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell)...

Sponsor: Ab&B Bio-tech Co., Ltd.JSEnrolling: 4701 location
RECRUITINGPhase 2NCT07092865

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and...

This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above...

Sponsor: GlaxoSmithKlineEnrolling: 18420 locations
RECRUITINGPhase 3NCT06775405

A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of...

Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.Enrolling: 18018 locations
RECRUITINGPhase 3NCT07543380

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections...

Sponsor: PfizerEnrolling: 1305 locations
RECRUITINGPhase 2NCT06665100

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial...

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections...

Sponsor: Pulmotect, Inc.Enrolling: 10011 locations
RECRUITINGNCT06639386

Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups

Achieving optimal vaccination rates is vital for protecting the health and well-being of all individuals. This specific study focuses on the MMR and RSV vaccines in pregnancy and...

Sponsor: Boston Medical CenterEnrolling: 801 location
RECRUITINGNCT06851806

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

This is a Phase IV, prospective, open-label, multicentre study to evaluate the safety of palivizumab IM injection for the prevention of severe LRTD in Indian infants and children...

Sponsor: AstraZenecaEnrolling: 1382 locations
RECRUITINGNCT06521944

RSV Vaccine Pregnancy Registry

The research question is: What is the risk of adverse pregnancy outcomes, including preterm birth, hypertensive disorders, and other maternal and neonatal/infant outcomes,...

Sponsor: CorEvitasEnrolling: 20621 location
RECRUITINGNCT06172660

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the...

Sponsor: Yale UniversityEnrolling: 37501 location
RECRUITINGNCT06511687

Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)

The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the...

Sponsor: Instituto Sistemas Complejos de IngenieríaEnrolling: 1600001 location
RECRUITINGPhase 2NCT06873633

Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV

THAI-CARES RSV Study is a Phase II, open-label, multicenter, randomized controlled trial with a two-arm, parallel-group design. The study aims to assess the safety, efficacy, and...

Sponsor: PENTA FoundationEnrolling: 1208 locations
RECRUITINGPhase 2NCT06817889

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or...

Sponsor: Fred Hutchinson Cancer CenterEnrolling: 603 locations
RECRUITINGPhase 3NCT06267118

Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis

The goal of this clinical trial is to compare the efficacy of hypertonic saline nebulization with adrenaline nebulization in the treatment of acute bronchiolitis in children. Main...

Sponsor: Combined Military Hospital, PakistanEnrolling: 601 location
RECRUITINGPhase 2 / Phase 3NCT07658534

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

Respiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised...

Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.Enrolling: 2909 locations
RECRUITINGNCT06827249

Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis

This is a multicenter, randomized, positive-controlled, non-inferiority clinical study, planning to enroll 90 children with bronchiolitis caused by respiratory syncytial virus...

Sponsor: Children's Hospital of Soochow UniversityEnrolling: 903 locations
RECRUITINGPhase 2NCT07633288

A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in...

A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in...

Sponsor: SynAct Pharma ApsEnrolling: 9611 locations
RECRUITINGNCT06197152

Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV

A short description, 5000 characters Intro: Respiratory Syncytial Virus (RSV) is a frequent, ubiquitous agent of respiratory viral infections. It is the leading viral cause of...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1331 location
RECRUITINGNCT06286007

Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control

The main objective is to estimate the annual symptomatic incidence of Bordetella pertussis and RSV infections in patients aged 18 years and over with asthma, which will be...

Sponsor: Hospital Clinico Universitario de SantiagoEnrolling: 7841 location
RECRUITINGNCT07147517

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the...

Sponsor: University of California, San DiegoEnrolling: 250002 locations

Showing 50 of 62 trials.Search all Respiratory Syncytial Virus (rsv) trials

Frequently Asked Questions

There are currently 62 clinical trials for Respiratory Syncytial Virus (rsv), with 62 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Respiratory Syncytial Virus (rsv), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 12 Phase 3 trials for Respiratory Syncytial Virus (rsv), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.